SonicShares Airlines, Hotels, Cruise Lines ETF (TRYP) Stock Price, News & Analysis

Company Overview

Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRYP Stock Analysis - Frequently Asked Questions

How do I buy shares of SonicShares Airlines, Hotels, Cruise Lines ETF?

Shares of TRYP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SonicShares Airlines, Hotels, Cruise Lines ETF own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SonicShares Airlines, Hotels, Cruise Lines ETF investors own include Trulieve Cannabis (TCNNF), Curaleaf (CURLF), Fernhill (FERN), Barrick Gold (GOLD), GrowGeneration (GRWG), Puget Technologies (PUGE) and Cassava Sciences (SAVA).

Industry, Sector and Symbol

• Stock Exchange: CNSX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CNSX:TRYP
• CIK: N/A
• Web: www.tryptherapeutics.com
• Phone: 833 811 8797
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A